Cold Chain-Free Storable Hydrogel for Infant-Friendly Oral Delivery of Amoxicillin for the Treatment of Pneumococcal Pneumonia

ACS Applied Materials & Interfaces
Keming XuChenjie Xu

Abstract

Pneumonia is the major cause of death in children under five, particularly in developing countries. Antibiotics such as amoxicillin greatly help in mitigating this problem. However, there is a lack of an infant/toddler-friendly formulation for countries with limited clean water orr electricity. Here, we report the development of a shear-thinning hydrogel system for the oral delivery of amoxicillin to infant/toddler patients, without the need of clean water and refrigeration. The hydrogel formulation consists of metolose (hydroxypropyl methylcellulose) and amoxicillin. It preserves the structural integrity of antibiotics and their antibacterial activity over 12 weeks at room temperature. Pharmacokinetic profiling of mice reveals that the hydrogel formulation increases the bioavailability of drugs by ∼18% compared to that with aqueous amoxicillin formulation. More importantly, oral gavage of this formulation in a mouse model of secondary pneumococcal pneumonia significantly ameliorates inflammatory infiltration and tissue damage in lungs, with a 10-fold reduction in bacterial counts compared to those in untreated ones. Given the remarkable antibacterial efficacy as well as the use of FDA-regulated ingredients (metolose and amoxic...Continue Reading

References

Oct 1, 1994·Journal of Clinical Pharmacy and Therapeutics·A C MehtaR W Lacey
Jan 11, 2000·International Journal of Food Sciences and Nutrition·B F GibbsC N Mulligan
Feb 28, 2002·Archives of Internal Medicine·J V Hirschmann
Dec 20, 2003·Lancet·Thomas M File
Apr 23, 2005·Archives of Disease in Childhood. Fetal and Neonatal Edition·T Duke
Nov 10, 2005·Journal of Biomedical Materials Research. Part a·Gisela HeleniusBo Risberg
Sep 26, 2006·Lancet·Tessa WardlawElizabeth Mason
Dec 5, 2006·International Journal of Pharmaceutics·Janez Kerč, Jerneja Opara
Mar 3, 2007·International Journal of Pharmaceutics·G CsókaI Antal
Apr 25, 2007·Journal of Pharmaceutical Sciences·Magali B HickeyOrn Almarsson
Oct 16, 2008·Clinical Microbiology Reviews·Damiana ChiavoliniSusanna Ricci
Jan 28, 2009·Pediatrics·Sarah A ThomsonAlastair G Sutcliffe
Feb 24, 2010·Computer Methods and Programs in Biomedicine·Yong ZhangShaofei Xie
Mar 12, 2011·Advanced Materials·Jason A Burdick, Glenn D Prestwich
Jun 7, 2011·International Journal of Pharmaceutics·Jennifer WalshUNKNOWN European Paediatric Formulation Initiative (EuPFI)
Jul 31, 2013·Biomacromolecules·Joseph R LottTimothy P Lodge
Oct 1, 2013·International Journal of Pharmaceutics·Baljit SinghAbhishek Dhiman
May 23, 2014·Expert Opinion on Drug Delivery·Lindsey A SharpeNicholas A Peppas
Oct 20, 2015·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·V BlancP-M Roger
Dec 1, 2015·Journal of Controlled Release : Official Journal of the Controlled Release Society·Michael Clinton KoettingNicholas A Peppas

❮ Previous
Next ❯

Citations

Aug 11, 2021·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Brinta BhattacharjeeJayanta Haldar

❮ Previous
Next ❯

Methods Mentioned

BETA
scanning electron microscopy

Software Mentioned

Excel
PKSolver

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.